PHARMACOECONOMIC ISSUES OF ADALIMUMAB THERAPY IN JUVENILE IDIOPATHIC ARTHRITIS

Background. Juvenile idiopathic arthritis (JIA) is the most common type of arthritis in children and is associated with reduced quality of life and increased health care costs. Objective. To evaluate the cost effectiveness of the tumour necrosis factor inhibitor adalimumab (ADA) vs. non-biologic the...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: K. Simpson, N. Marlow, J. Shaw, А. V. Rudakova
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Paediatrician Publishers, LLC 2012-08-01
Seri Bilgileri:Pediatričeskaâ Farmakologiâ
Konular:
juvenile idiopathic arthritis
adalimumab
cost-effectiveness analysis
Online Erişim:https://www.pedpharma.ru/jour/article/view/302
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller